×

Biotech and Pharmaceuticals Pharmaceuticals

  • Oct 17- A U.S. judges ruling on Monday invalidating Allergan Plc's patents on its blockbuster $1.5 billion dry-eye medicine, Restasis, has cast doubt on the company's novel strategy to enlist a Native American tribe to help shield those patents from challenge by generic drugmakers, legal experts said. In a deal announced last month, Allergan transferred the...

  • Oct 17- Johnson& Johnson posted better-than-expected third-quarter earnings, raising its full-year forecast due to growth from new cancer drugs and high-margin treatments picked up in its $30 billion acquisition of Actelion earlier this year. Shares of J&J, part of the Dow Jones Industrial Average, rose 3.4 percent to $140.79 on Tuesday.

  • Oct 17- Johnson& Johnson posted better-than-expected third-quarter earnings, raising its full-year forecast due to growth from new cancer drugs and high-margin treatments picked up in its $30 billion acquisition of Actelion earlier this year. Shares of J&J, part of the Dow Jones Industrial Average, rose 2.4 percent to $139.37 on Tuesday.

  • Bill George: Trump is right, drug prices are out of control

    Bill George, CNBC contributor and former Medtronic CEO, discusses President Trump's rhetoric on prescription drug pricing in the country.

  • WASHINGTON, Oct 17- President Donald Trump said on Tuesday that Tom Marino, his pick as the U.S. drug czar, has withdrawn after it became public that the congressman advocated for legislation undermining the government's ability to crack down on pharmaceutical companies that play a role in the nation's opioid crisis. Trump had pegged Marino, a Pennsylvania...

  • Rep. Tom Marino, R-Pa.

    A WashPost/CBS investigation said Marino was the "chief advocate" for a drug industry-friendly law that hobbled the fight against opioid abuse.

  • JNJ CFO: We price our products responsibly

    Dominic Caruso, Johnson & Johnson CFO breaks down the company's quarterly results and weighs in on whether he expects to see disruption in Puerto Rico manufacturing, and comments on drug pricing.

  • Trump: I'm not interested in drug companies' money

    CNBC's Eamon Javers reports on President Trump's agenda, including meeting with GOP leader Mitch McConnell, making lower prescription drug prices a priority and possibly delaying tax reform until 2018.

  • Donald Trump

    President Donald Trump on Monday complained that drug prices are too high and said "massive" campaign contributions to Congress are partly to blame.

  • Judge William Bryson issued the ruling in federal court in Marshall, Texas, in a longstanding dispute between Allergan and generic drugmakers Mylan NV, Teva Pharmaceutical Industries Ltd and Akorn Inc.. "What Allergan seeks is the right to continue to enjoy the considerable benefits of the U.S. patent system without accepting the limits that Congress has...

  • Donald Trump

    Barbara Ryan, Barbara Ryan Advisors, discusses President Trump's claims that pharmaceutical companies are "getting away with murder" with prescription drug pricing.

  • Judge William Bryson issued the ruling in federal court in Marshall, Texas, in a longstanding dispute between Allergan and generic drugmakers led by Mylan NV and Teva Pharmaceutical Industries Ltd.. The drug generated around $1.5 billion in sales for Allergan last year and accounted for more than 10 percent of the company's revenue. Senator Claire McCaskill...

  • Oct 16- Shares of pharmaceutical company Allergan Plc dropped on Monday after a ruling by a U.S. judge invalidated patents on its dry eye medicine Restasis on the grounds that the patents cover obvious ideas. Judge William Bryson issued the ruling in federal court in Marshall, Texas, in a longstanding dispute between Allergan and generic drugmakers led by Mylan...

  • Oct 16- A U.S. judge on Monday invalidated patents issued to Allergan Plc on its dry eye medicine Restasis, saying they covered ideas that were too obvious to protect. Judge William Bryson issued the ruling in federal court in Marshall, Texas, in a longstanding dispute between Allergan and generic drugmakers led by Mylan NV and Teva Pharmaceutical Industries...

  • RULING BY FEDERAL JUDGE IN TEXAS IS VICTORY FOR GENERIC DRUGMAKERS MYLAN, TEVA.

  • *Some small consultancies relocating from Britain. LONDON, Oct 16- Drugmakers and medical devices companies are drawing up plans to protect supply chains in case Britain crashes out of the European Union without a trade deal, and some small service businesses are already relocating to stay inside the bloc. "Clearly, if the UK is no longer in the EU, we will be no more...

  • Opioids

    Lenny Bernstein, The Washington Post, talks about the Drug Enforcement Administration's efforts to fight the opioid crisis in America.

  • *Bayer gains after $7 billion disposal; BASF falls. *Profit warning hits UK engineer GKN. LONDON/ MILAN, Oct 13- European shares hit their highest in nearly four months on Friday, helped by gains in Bayer, after the German drugmaker sold assets that will pave the way for its acquisition of Monsanto.

  • ZURICH, Oct 13- Swiss drugmaker Roche's Alecensa has been recommended for approval in Europe as a first-line treatment for mutated lung cancer, a key European Medicines Agency experts panel said on Friday. Zuercher Kantonalbank analyst Michael Nawrath estimates annual sales of Alecensa will hit 1.4 billion Swiss francs by 2024 and capture about 70 percent...

  • BERLIN— German pharmaceutical giant Bayer AG has reached a 5.9 billion euro deal to sell parts of its Crop Science unit to German chemical company BASF to alleviate regulatory concerns over its planned takeover of U.S. seed and weed-killer company Monsanto Co.. Monsanto last year accepted an offer from Bayer to pay $57 billion to its shareholders and assume $9...